Latest Articles

Publication Date
An integrated multimodal approach to drug repurposing in endometriosis, using ROR1 as a target.

Endometriosis is a chronic, heterogeneous disease with limited non-hormonal treatment options. Drug repurposing provides an accelerated route to identify safe, tolerable, and potentially effective therapies for endometriosis. Receptor tyrosine kinase-like …

Published: Dec. 3, 2025, midnight
Emerging roles and therapeutic potential of tRNA-Derived small RNAs in reproductive system diseases: a review.

tRNA-derived small RNAs (tsRNAs) are a class of non-coding RNAs(ncRNAs) generated from precursor or mature tRNAs under stress conditions, such as starvation, hypoxia, or oxidative stress. They are broadly classified …

Published: Dec. 3, 2025, midnight
Experts establish diagnostic criteria for primary dysmenorrhea - Contemporary OB/GYN

Experts establish diagnostic criteria for primary dysmenorrhea Contemporary OB/GYN

Published: Dec. 2, 2025, 4:47 p.m.
How invisible symptoms and provider bias delay endometriosis diagnosis - Contemporary OB/GYN

How invisible symptoms and provider bias delay endometriosis diagnosis Contemporary OB/GYN

Published: Dec. 2, 2025, 2:02 p.m.
Metri Bio Raises $5M Pre-Seed to Develop Endometriosis Therapeutics - Femtech Insider

Metri Bio Raises $5M Pre-Seed to Develop Endometriosis Therapeutics Femtech Insider

Published: Dec. 2, 2025, 1:03 p.m.
Singapore start-up raises US$1.5m to redefine menstrual health - FemTech World

Singapore start-up raises US$1.5m to redefine menstrual health FemTech World

Published: Dec. 2, 2025, 12:49 p.m.
Ziwig Publishes Validation Study for Saliva-Based Endometriosis Test - Femtech Insider

Ziwig Publishes Validation Study for Saliva-Based Endometriosis Test Femtech Insider

Published: Dec. 2, 2025, 11:38 a.m.
Round up: First wearable detects symptoms of perimenopause, and more - FemTech World

Round up: First wearable detects symptoms of perimenopause, and more FemTech World

Published: Dec. 2, 2025, 11:04 a.m.
Bayer starts Phase III study with long-acting reversible intrauterine system for treatment of nonatypical endometrial hyperplasia - Bayer

Bayer starts Phase III study with long-acting reversible intrauterine system for treatment of nonatypical endometrial hyperplasia Bayer

Published: Dec. 2, 2025, 7:30 a.m.
Amy Schumer’s Ozempic Journey: Hollywood’s Health-First Weight Loss Trend - Zoom Bangla News

Amy Schumer’s Ozempic Journey: Hollywood’s Health-First Weight Loss Trend Zoom Bangla News

Published: Dec. 2, 2025, 6:18 a.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!